CV

CVRx IncNASDAQ CVRX Stock Report

Last reporting period 30 Sep, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

0.197

Micro

Exchange

XNAS - Nasdaq

CVRX Stock Analysis

CV

Uncovered

CVRx Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-26/100

Low score

Market cap $B

0.197

Dividend yield

Shares outstanding

20.69 B

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.

View Section: Eyestock Rating